I-Mab, ABL Bio Announce Latest Updates of PD-L1 And 4-1BB Bispecific Antibody TJ-L14B/ABL503
Portfolio Pulse from Benzinga Newsdesk
I-Mab and ABL Bio have announced updates on their ongoing Phase 1 study of bispecific antibody TJ-L14B/ABL503. Among 14 efficacy-evaluable patients, one achieved a complete response, one had a partial response and two unconfirmed partial responses. The maximum tolerated dose has not yet been reached. Patent rights for TJ-L14B/ABL503 have been secured in Eurasia until 2039.
October 10, 2023 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
I-Mab's ongoing Phase 1 study of TJ-L14B/ABL503 shows promising results, with patent rights secured until 2039. This could potentially boost the company's stock in the short term.
The positive results from the ongoing Phase 1 study of TJ-L14B/ABL503, along with the secured patent rights, could potentially increase investor confidence in I-Mab, leading to a short-term increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100